Synthetic Biologics, Inc. (SYN)
Stock Price:
$0.560 USD
0.003 (0.47%)
Updated Aug 14, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
10.89M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-14.09M |
| Shares Out |
19.44M |
| EPS (ttm) |
-0.88 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 14, 2020 |
| Last Price |
$0.560 |
| Previous Close |
$0.557 |
| Change ($) |
0.003 |
| Change (%) |
0.47% |
| Day's Open |
0.550 |
| Day's Range |
0.550 - 0.576 |
| Day's Volume |
105,964 |
| 52-Week Range |
0.252 - 0.750 |
More Stats
| Market Cap |
10.89M |
| Enterprise Value |
3.43M |
| Earnings Date (est) |
Nov 5, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
19.44M |
| Float |
19.30M |
| EPS (basic) |
-0.88 |
| EPS (diluted) |
-0.88 |
| FCF / Share |
-0.74 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
117,280 |
| Short Ratio |
0.17 |
| Short % of Float |
0.61% |
| Beta |
1.97 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
77.81 |
| Revenue |
n/a |
| Operating Income |
-14.37M |
| Net Income |
-14.09M |
| Free Cash Flow |
-13.65M |
| Net Cash |
7.46M |
| Net Cash / Share |
0.38 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-53.49% |
| ROE |
-111.53% |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (2)
| Buy |
2 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$1.38*
(146.43% upside)
Low
1.25
Current: $0.560
High
1.50
Target: 1.38
*Average 12-month price target from 2 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | - | - | - | - | - | - | - | - | - | 2.61 |
| Gross Profit | - | - | - | - | - | - | - | - | - | 2.61 |
| Operating Income | -15.66 | -17.57 | -26.25 | -39.25 | -40.98 | -20.50 | -12.34 | -17.30 | -5.93 | -1.08 |
| Net Income | -15.30 | -13.37 | -15.17 | -27.26 | -43.74 | -19.78 | -12.32 | -17.07 | -8.15 | -1.71 |
| Shares Outstanding | 16.44 | 6.23 | 3.55 | 2.69 | 2.31 | 1.77 | 1.30 | 1.00 | 0.79 | 0.64 |
| Earnings Per Share | -0.98 | -4.06 | -6.23 | -10.15 | -18.90 | -11.20 | -9.45 | -17.15 | -10.15 | -2.80 |
| Operating Cash Flow | -13.87 | -17.28 | -20.20 | -27.90 | -38.89 | -16.08 | -7.72 | -8.92 | -2.88 | -1.15 |
| Capital Expenditures | - | -0.01 | -0.21 | -0.57 | -0.50 | -0.05 | -0.04 | -0.01 | - | 0.07 |
| Free Cash Flow | -13.87 | -17.29 | -20.42 | -28.47 | -39.39 | -16.13 | -7.76 | -8.93 | -2.87 | -1.08 |
| Cash & Equivalents | 15.05 | 28.92 | 17.12 | 19.06 | 20.82 | 17.53 | 14.63 | 9.95 | 6.68 | 2.65 |
| Total Debt | 0.72 | - | - | - | - | - | - | - | - | - |
| Net Cash / Debt | 14.32 | 28.92 | 17.12 | 19.06 | 20.82 | 17.53 | 14.63 | 9.95 | 6.68 | 2.65 |
| Assets | 17.24 | 30.14 | 18.84 | 22.50 | 30.85 | 19.14 | 16.26 | 13.42 | 7.48 | 4.11 |
| Liabilities | 5.75 | 3.69 | 10.20 | 20.25 | 15.84 | 9.59 | 1.03 | 0.40 | 0.42 | 0.53 |
| Book Value | 1.82 | 17.07 | -1.50 | 3.85 | 16.05 | 9.56 | 15.23 | 13.03 | 7.06 | 3.58 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Synthetic Biologics, Inc. |
| Country |
United States |
| Employees |
11 |
| CEO |
Steven A. Shallcross |
Stock Information
| Ticker Symbol |
SYN |
| Stock Exchange |
NYSE American |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NYSEAMERICAN: SYN |
| IPO Date |
June 26, 2006 |
Description
Synthetic Biologics, Inc., a clinical-stage company develops therapeutics to treat gastrointestinal diseases in the United States. Its lead product candidates include SYN-004 that has completed Phase II clinical trial designed to degrade commonly used intravenous beta-lactam antibiotics in gastrointestinal tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease in allogeneic hematopoietic cell transplant recipients. The company is also developing SYN-010 that is in Phase IIb/III clinical trial to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation; and SYN-020, an early-stage oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. In addition, its clinical stage products include SYN-006 and SYN-007 for the prevention of CDI, overgrowth of pathogenic organisms, and AMR; and SYN-005 for the prevention and treatment of pertussis. Synthetic Biologics, Inc. has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. The company is headquartered in Rockville, Maryland.